BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on SGLT2 inhibitors: Risk of diabetic ketoacidosis

2015.07.10

Active substance: canagliflozin, capagliflozin, empagliflozin

The companies AstraZeneca AB, Boehringer Ingelheim International GmbH and Janssen-Cilag International N.V. are circulating information on the risk of diabetic ketoacidosis under treatment with SGLT2 inhibitors.

Details on the procedure can be found on the website of the European Medicines Agency (EMA):

SGLT2 inhibitors

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 186KB, File is accessible